メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
波多野 正和
臨床薬剤科
h-index
247
被引用数
9
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2013
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(42)
類似のプロファイル
(6)
フィンガープリント
Masakazu Hatanoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
100%
Aripiprazole
69%
Remission
49%
Adverse Event
49%
Typical Antipsychotic
49%
Polypharmacy
46%
Clozapine
46%
Recurrent Disease
43%
Symptom
43%
Treatment-Resistant Schizophrenia
43%
Major Depression
43%
Headache
43%
Random Effects Model
30%
Placebo
26%
Paliperidone
26%
Risperidone
26%
Cohort Study
25%
Diazepam
24%
Observational Study
23%
Depression
22%
Febrile Neutropenia
21%
Aspartate Aminotransferase
21%
Cisplatin
21%
Recurrence Risk
21%
Antidepressant
21%
Bipolar Mania
21%
Disease
21%
Lamictal
21%
Bipolar I Disorder
21%
Olanzapine
21%
Drug Administration
21%
Hemoglobin A1c
21%
Fluorouracil
21%
High Density Lipoprotein Cholesterol
21%
Population Study
21%
Asenapine
21%
Monotherapy
21%
Controlled Release
21%
Randomized Controlled Trial
21%
Vortioxetine
21%
Mixed Anxiety and Depression
16%
Cariprazine
13%
Chronic Kidney Failure
10%
Triacylglycerol
10%
Bipolar Disorder
10%
Metabolic Syndrome X
10%
Chronic Liver Disease
10%
Cross-Sectional Study
10%
Adverse Drug Reaction
10%
Alanine Aminotransferase
10%
Keyphrases
Meta-analysis
45%
Major Depressive Disorder
45%
Newer Antidepressants
43%
Systematic Meta-analysis
43%
Left DLPFC
36%
Japan
34%
Pairwise Meta-analysis
32%
Confidence Interval
29%
Antidepressants
28%
Antipsychotics
25%
Vortioxetine
24%
Patients with Schizophrenia
21%
Febrile Neutropenia
21%
Older People
21%
Subjective Survey
21%
Bipolar Mania
21%
Long-acting Injectable Aripiprazole
21%
Neutrophil-lymphocyte Ratio
21%
Long-acting Injection
21%
Muscle Injection
21%
Lamotrigine
21%
Enrichment Design
21%
Japanese Adverse Drug Event Report (JADER)
21%
5-fluorouracil (5-FU)
21%
Clozapine
21%
Deltoid Injection
21%
Cisplatin
21%
Trends Survey
21%
Monotherapy
21%
Treatment-resistant Schizophrenia
21%
Antipsychotic Polypharmacy
21%
Work Outcomes
21%
Mirror-image Study
21%
Intermittent theta Burst Stimulation (iTBS)
21%
Japanese Adults
21%
Standardized Mean Difference
20%
Risk Ratio
19%
Japanese Patients
18%
Depressive Symptoms
17%
Placebo
16%
High-dose Antipsychotics
16%
Pharmacist-led
14%
Randomized Placebo-controlled Trial
13%
Symptom Scale
13%
Cariprazine
13%
Gluteal Injection
13%
Clozapine Discontinuation
13%
Adverse Events
12%
Outpatient Department
10%
Social Rehabilitation
10%
Neuroscience
Meta-Analysis
86%
Major Depressive Disorder
50%
Clozapine
43%
Treatment-Resistant Schizophrenia
43%
Dorsolateral Prefrontal Cortex
43%
Antidepressant
43%
Placebo
27%
Dementia Praecox
24%
Benzodiazepine Receptor
21%
Receptor Agonists
21%
Suvorexant
21%
Mixed Anxiety and Depression
21%
Asenapine
21%
Typical Antipsychotic
16%
Occipital Lobe
14%
Prefrontal Cortex
14%
Headache
14%
Depression
11%
Adverse Effect
9%
Antipsychotic
7%
Treatment of Depression
7%
Randomized Controlled Trial
7%
Schizoaffective Disorder
7%
